STOCK TITAN

Avalo Therapeutics (AVTX) Stock Price, News & Analysis

AVTX NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
66 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
-39.2% close of October 22, 2026
1-year change
-61.9% closing prices, November 20, 2025 to November 20, 2026
1-month change
-45.3% closing prices, October 20, 2026 to November 20, 2026

Company Description

Avalo Therapeutics, Inc. (NASDAQ: AVTX) is a clinical stage biotechnology company focused on the treatment of immune dysregulation and immune-mediated inflammatory diseases. According to the company’s public statements, Avalo is fully dedicated to developing IL‑1β‑based treatments for these conditions, with its work centered on targeted monoclonal antibody therapies.

Avalo’s business is built around the research, development and clinical testing of biologic drug candidates. The company’s lead asset is AVTX‑009, described as a humanized monoclonal antibody (IgG4) that binds to interleukin‑1β (IL‑1β) with high affinity and neutralizes its activity. IL‑1β is characterized in Avalo’s materials as a pro‑inflammatory cytokine that plays a central role in the pathogenesis of a wide range of human diseases and is a major, validated target for therapeutic intervention. Dysregulated IL‑1β signaling is cited as a major driver of inflammation and the progression of autoimmune and other inflammatory disorders.

Clinical focus and lead program

The company reports that AVTX‑009 is in a Phase 2 clinical trial for hidradenitis suppurativa (HS), referred to as the LOTUS trial. HS is described in Avalo’s disclosures as a chronic, progressive, often debilitating inflammatory skin disease that causes painful nodules, abscesses and tunnels to form under the skin. The disease is associated with chronic inflammation that can lead to tissue destruction and permanent scarring if not adequately treated. Avalo highlights HS as a condition with significant remaining unmet medical need.

The LOTUS trial is described as a randomized, double‑blind, placebo‑controlled, parallel‑group Phase 2 study in adults with moderate to severe HS. Subjects are randomized to receive one of two AVTX‑009 dosing regimens or placebo over a 16‑week treatment phase. The primary efficacy endpoint disclosed by the company is the proportion of subjects achieving Hidradenitis Suppurativa Clinical Response at the 75% level (HiSCR75) at Week 16. Secondary objectives include the proportion of patients achieving HiSCR50 and HiSCR90, and changes from baseline in several HS disease activity measures and patient‑reported skin pain assessments.

Scientific and therapeutic rationale

In its public descriptions, Avalo emphasizes the central role of IL‑1β in inflammation. IL‑1β is said to activate immune cells that generate additional pro‑inflammatory cytokines, including IL‑6, TNF‑α and IL‑17. The company notes that IL‑1β overproduction or dysregulation is implicated in many autoimmune and inflammatory diseases, and that IL‑1β inhibition has proven effective in multiple immune‑mediated inflammatory diseases. This scientific rationale underpins Avalo’s focus on IL‑1β‑targeted therapies and the development of AVTX‑009.

Avalo’s disclosures also reference broader potential for IL‑1β inhibition beyond HS. The company notes evidence that IL‑1β inhibition could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology and rheumatology, and that it is exploring additional opportunities in prevalent indications with significant unmet needs. These statements frame Avalo’s strategy as concentrating on immune dysregulation and inflammatory pathways where IL‑1β is a key driver.

Pipeline and development orientation

Public materials indicate that Avalo is a clinical‑stage organization, with its efforts focused on advancing AVTX‑009 through clinical development. Earlier descriptions of the company’s pipeline reference additional assets, including quisovalimab (an anti‑LIGHT monoclonal antibody) and AVTX‑008 (a BTLA agonist fusion protein), but current company communications consistently highlight AVTX‑009 as the lead asset and central development priority.

The company’s reported activities include conducting global clinical trials, preparing for data readouts, and planning for potential later‑stage development. Avalo also reports efforts to expand its leadership team and board of directors with individuals experienced in clinical development, regulatory strategy, business development and capital markets, reflecting a focus on executing its development plans and corporate strategy around immune‑mediated inflammatory diseases.

Regulatory and public company status

Avalo Therapeutics, Inc. is incorporated in Delaware and files reports with the U.S. Securities and Exchange Commission under Commission File Number 001‑37590. The company’s common stock trades on The Nasdaq Capital Market under the ticker symbol AVTX. Recent Form 8‑K filings describe events such as financial results announcements, updates to investor presentations, and appointments of directors and senior executives, illustrating the company’s status as an actively reporting public issuer.

Through these filings and press releases, Avalo presents itself as a biotechnology company in the pharmaceutical preparation manufacturing sector, with a specialized focus on IL‑1β‑targeted biologics for immune‑mediated inflammatory diseases. Investors and observers looking at AVTX stock are primarily evaluating the progress, safety and efficacy data of AVTX‑009 in hidradenitis suppurativa and the broader potential of IL‑1β‑based approaches in immune dysregulation.

Position within the biotechnology landscape

Within the broader biotechnology and pharmaceutical preparation manufacturing sector, Avalo’s niche is defined by its concentration on immune dysregulation and IL‑1β biology. Rather than a broad portfolio across many mechanisms, the company’s public communications emphasize a focused approach on IL‑1β‑based treatments and on immune‑mediated inflammatory diseases where this pathway is believed to be central. This specialization shapes its clinical trial design, scientific rationale and investor communications.

For market participants researching AVTX stock, key themes in Avalo’s disclosures include the mechanism of action of AVTX‑009, the design and endpoints of the LOTUS Phase 2 trial in HS, the scientific justification for targeting IL‑1β in immune‑mediated inflammatory diseases, and the company’s intention to explore additional indications where IL‑1β‑driven inflammation plays a significant role.

Key points for AVTX investors

  • A clinical stage biotechnology company focused on immune dysregulation and immune‑mediated inflammatory diseases.
  • Lead asset AVTX‑009, a humanized monoclonal antibody targeting IL‑1β, in Phase 2 development for hidradenitis suppurativa.
  • Strategic emphasis on IL‑1β as a central driver of inflammation and a validated therapeutic target.
  • Public company listed on The Nasdaq Capital Market under the symbol AVTX, incorporated in Delaware.
  • Ongoing clinical and corporate updates communicated through press releases and SEC filings, including Form 8‑K reports.

Stock Performance

$6.76
+0.15%
+0.01
Last updated: at
-61.9%
Performance 1 year
$390.9M

Avalo Therapeutics (AVTX) closed at $6.76 on November 20, 2026. Over the past 12 months, the price has lost 61.9%.

See what a $1,000 investment in AVTX would be worth today

Average down calculator for AVTX

AVTX Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
23,258
Shares Sold
3
Transactions
Most Recent Transaction
Sullivan Christopher Ryan (Chief Financial Officer) sold 12,394 shares @ $16.33 on September 16, 2026

Insider selling at Avalo Therapeutics over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Avalo Therapeutics generated $59K in revenue in FY2025, operating income reached -$72.9M, and net income was -$78.3M. Diluted earnings per share stood at -$5.84. The company generated -$51.5M in operating cash flow. The current ratio was 8.14, measuring current assets divided by current liabilities.

$59K
Revenue (FY2025)
-$78.3M
Net Income (FY2025)
-$51.5M
Operating Cash Flow

Upcoming Events

H1
2027
H1 2027 Clinical

Abdakibart Phase 3 Start

Registrational Phase 3 initiation for abdakibart in hidradenitis suppurativa targeted H1 2027; protocol details to follow.
H1
2027
H1 2027 Regulatory

AVTX-010 IND Submission

Planned IND submission for AVTX-010, a long-acting anti-IL-1β antibody, targeted in H1 2027; FDA review to follow.
H1
2027
H1 2027 Regulatory

IND submission planned

Planned IND filing for AVTX-010 in H1 2027 to enable clinical trials in HS; no submission date or agency specified.
H1
2027
H1 2027 Clinical

Phase 3 program start

Start of Phase 3 program for abdakibart in hidradenitis suppurativa planned in H1 2027; study initiation and sites to be announced.
H1
2027
H1 2027 Regulatory

AVTX-010 IND filing

Application to begin clinical testing of AVTX-010 anticipated in H1 2027; plans for first-in-human study to follow.
FEB
13
February 13, 2027 Corporate

25% option vesting cliff

25% of 82,000 options vest; exercisable at $14.26; grant dated 2026-02-13
SEP
02
September 2, 2027 - September 2, 2030 Corporate

Employee option vesting

78,000 options (granted 2026-09-02) vest 25% on 2027-09-02 then monthly over 36 months; exercise price $19.34.
FEB
13
February 13, 2030 Corporate

Remaining options fully vested

Remaining 75% vests monthly over 36 months; all options vested and exercisable at $14.26

Avalo Therapeutics has 8 upcoming scheduled events. The next event, "Abdakibart Phase 3 Start", is expected in H1 2027. Investors can track these dates to stay informed about potential catalysts that may affect the AVTX stock price.

Short Interest History

Last 12 Months

Short interest in Avalo Therapeutics (AVTX) currently stands at 8.9 million shares, down 25.5% from the previous reporting period, representing 15.7% of the float. Since November 2025, short interest has increased by 382.1%.

Days to Cover History

Last 12 Months

Days to cover for Avalo Therapeutics (AVTX) currently stands at 2.1 days, down 83.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 60%. Across the settlements charted above, it has ranged from 1.6 to 20.2 days.

AVTX Company Profile & Sector Positioning

Avalo Therapeutics (AVTX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing AVTX often look at related companies in the same sector, including Shattuck Labs, Inc. (STTK), Assembly Biosciences, Inc (ASMB), Gyre Therapeutics, Inc. (GYRE), Arvinas, Inc (ARVN), and CytomX Therapeutics, Inc. (CTMX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate AVTX's relative position within its industry.

Frequently Asked Questions

The current stock price of Avalo Therapeutics (AVTX) is $6.76 as of November 20, 2026.

The market cap of Avalo Therapeutics (AVTX) is approximately $390.9M. Learn more about what market capitalization means .

The FY2025 revenue of Avalo Therapeutics (AVTX) is $59K, from its most recent completed fiscal year.

The FY2025 net income of Avalo Therapeutics (AVTX) is -$78.3M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Avalo Therapeutics (AVTX) is -$5.84 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Avalo Therapeutics (AVTX) is -$51.5M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Avalo Therapeutics (AVTX), current assets divided by current liabilities, was 8.14 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Avalo Therapeutics (AVTX) is -$72.9M for FY2025, its most recent completed fiscal year. Learn about operating income.

Avalo Therapeutics, Inc. focuses on the treatment of immune dysregulation and immune-mediated inflammatory diseases. The company describes itself as a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments, with its work centered on monoclonal antibody drug candidates.

AVTX-009 is Avalo’s lead asset, described as a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is characterized as a pro-inflammatory cytokine that activates immune cells and contributes to the progression of autoimmune and inflammatory diseases, making it a major, validated target for therapeutic intervention.

Avalo reports that the LOTUS trial is a Phase 2 clinical study of AVTX-009 in adults with moderate to severe hidradenitis suppurativa (HS). HS is described as a chronic, progressive, often debilitating inflammatory skin disease with painful nodules, abscesses and tunnels under the skin.

The LOTUS trial is described as a randomized, double-blind, placebo-controlled, parallel-group Phase 2 study with two AVTX-009 dose regimens. Adults with moderate to severe hidradenitis suppurativa are randomized to receive one of two AVTX-009 dosing regimens or placebo during a 16-week treatment phase. The primary endpoint is the proportion of subjects achieving HiSCR75 at Week 16, with several secondary efficacy measures also evaluated.

In its public materials, Avalo cites evidence that IL-1β is a central driver in the inflammatory process. IL-1β is said to activate immune cells that generate additional pro-inflammatory cytokines such as IL-6, TNF-α and IL-17. Overproduction or dysregulation of IL-1β is described as being implicated in many autoimmune and inflammatory diseases, and IL-1β inhibition has been effective in multiple immune-mediated inflammatory diseases.

Yes. Avalo states that it is exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. The company also notes evidence that IL-1β inhibition could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology and rheumatology.

Avalo describes hidradenitis suppurativa as a chronic, progressive, often debilitating inflammatory skin disease that causes painful nodules, abscesses and tunnels to form under the skin. The company notes that areas commonly affected include several body regions and that chronic inflammation in HS may progress to tissue destruction and permanent scarring if not adequately treated.

Avalo Therapeutics, Inc. states that its common stock trades on The Nasdaq Capital Market under the ticker symbol AVTX. The company is incorporated in Delaware and files reports with the U.S. Securities and Exchange Commission, including current reports on Form 8-K describing material events.

Recent Form 8-K filings from Avalo describe events such as the announcement of quarterly financial results, the posting of updated investor presentations, the completion of enrollment in the LOTUS Phase 2 trial of AVTX-009 for hidradenitis suppurativa, and the appointment of new directors and senior executives, along with related equity awards and compensation arrangements.